Novel Pharmaceutics Institute Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2011 | 140,853 | 194,689 | −53,836 | 2.2 | — |
| 2012 | 218,087 | 231,577 | −13,490 | 1.4 | 0% |
| 2013 | 652,896 | 578,608 | 74,288 | 2.1 | 0% |
| 2014 | 784,424 | 825,967 | −41,543 | 0.9 | 0% |
| 2015 | 735,251 | 784,293 | −49,042 | 0.2 | 0% |
| 2016 | 126,261 | 185,210 | −58,949 | -3.2 | 0% |
| 2017 | 579,733 | 170,487 | 409,246 | 25.4 | 0% |
| 2018 | 34,969 | 108,639 | −73,670 | 31.7 | 0% |
| 2019 | 60,850 | 316,600 | −255,750 | 1.2 | 0% |
| 2020 | 31,530 | 34,892 | −3,362 | 9.4 | 0% |
| 2021 | 7,129 | 12,330 | −5,201 | 21.7 | 0% |
| 2022 | 0 | 21,326 | −21,326 | 0.5 | 0% |
| 2023 | 0 | 2,672 | −2,672 | -7.8 | 0% |
In its most recent public year (2023), this organization spent $2,672 more than it brought in. Its liabilities exceeded its net assets — reserves were below zero (-7.8 months), down from 2.2 in 2011. Staff pay was 0% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
A new entry when its next filing is released. No account, no email; works in any feed reader, Slack, or automation tool. How following works